NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols
Executive Summary
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.